Evidence map›Paper›PMID 41623364›Full record

ArticleBlood vessels, thrombosis & hemostasis2026

Alpelisib, a PI3Kα inhibitor, effectively treats vascular anomalies with diverse genotypes and phenotypes.

Deeti J Pithadia, Marina J Heskel, Arman Shotayev, Sunit Davda, Rachelle Durand, Daniel Cooke, Josephine Czechowicz, Mary Lesh, Patricia Cornett, Kristin A Shimano and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Sirolimus outperforms alpelisib in models ofBlood vessels, thrombosis & hemostasis · 2026
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Deeti J PithadiaDivision of Pediatric Dermatology, Department of Dermatology, University of California San Francisco, San Francisco, CA.
Marina J HeskelDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA.
Arman ShotayevDivision of Pediatric Dermatology, Department of Dermatology, University of California San Francisco, San Francisco, CA.
Sunit DavdaDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA.
Rachelle DurandDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA.
Daniel CookeDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA.
Josephine CzechowiczDepartment of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, CA.
Mary LeshDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA.
Patricia CornettDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA.
Kristin A ShimanoDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA.
Erin F MathesDivision of Pediatric Dermatology, Department of Dermatology, University of California San Francisco, San Francisco, CA.
Ilona J FriedenDivision of Pediatric Dermatology, Department of Dermatology, University of California San Francisco, San Francisco, CA.
Beth Apsel WingerDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular anomalies (VAs) are complex, highly morbid conditions that are increasingly managed by hematologists with targeted therapies. They are often driven by activating mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Alpelisib, a phosphoinositide 3-kinase-α (PI3Kα) inhibitor, is a key therapy for VAs; however, it is only approved for

Identifiers

PMID41623364
PMCPMC12859186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.